WorldViewExplore

In the modern era of medical breakthroughs, cancer research has evolved at an astounding pace. Precision medicine, immunotherapy, and targeted therapies offer renewed hope for millions. However, behind this narrative of progress lies a darker reality—pharmaceutical inequality. New cancer drugs, though revolutionary, remain inaccessible to a large segment of the global population. Why are these life-saving treatments reserved only for the wealthy? And how has this pharmaceutical gap deepened the divide between rich and poor patients worldwide? The Cost of Survival: A Billionaire’s Medicine Cabinet Imagine being diagnosed with a rare form of cancer that now has a targeted drug approved by the FDA. This drug could extend your life by years—but it costs $400,000 per year. For many patients in the U.S., let alone in developing countries, this price tag is more than just unaffordable—it’s impossible. Major pharmaceutical companies argue that these prices reflect years of research...